Literature DB >> 22481268

Nonproteolytic properties of murine alternatively spliced tissue factor: implications for integrin-mediated signaling in murine models.

Richard C Godby1, Yascha W Van Den Berg, Ramprasad Srinivasan, Robert Sturm, David Y Hui, Stephen F Konieczny, Bruce J Aronow, Evgeny Ozhegov, Wolfram Ruf, Henri H Versteeg, Vladimir Y Bogdanov.   

Abstract

This study was performed to determine whether murine alternatively spliced tissue factor (masTF) acts analogously to human alternatively spliced tissue factor (hasTF) in promoting neovascularization via integrin ligation. Immunohistochemical evaluation of a spontaneous murine pancreatic ductal adenocarcinoma model revealed increased levels of masTF and murine full-length tissue factor (mflTF) in tumor lesions compared with benign pancreas; furthermore, masTF colocalized with mflTF in spontaneous aortic plaques of Ldlr(-/-) mice, indicating that masTF is likely involved in atherogenesis and tumorigenesis. Recombinant masTF was used to perform in vitro and ex vivo studies examining its integrin-mediated biologic activity. Murine endothelial cells (ECs) rapidly adhered to masTF in a β3-dependent fashion. Using adult and embryonic murine ECs, masTF potentiated cell migration in transwell assays. Scratch assays were performed using murine and primary human ECs; the effects of masTF and hasTF were comparable in murine ECs, but in human ECs, the effects of hasTF were more pronounced. In aortic sprouting assays, the potency of masTF-triggered vessel growth was undistinguishable from that observed with hasTF. The proangiogenic effects of masTF were found to be Ccl2-mediated, yet independent of vascular endothelial growth factor. In murine ECs, masTF and hasTF upregulated genes involved in inflammatory responses; murine and human ECs stimulated with masTF and hasTF exhibited increased interaction with murine monocytic cells under orbital shear. We propose that masTF is a functional homolog of hasTF, exerting some of its key effects via β3 integrins. Our findings have implications for the development of murine models to examine the interplay between blood coagulation, atherosclerosis and cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22481268      PMCID: PMC3409277          DOI: 10.2119/molmed.2011.00416

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  46 in total

Review 1.  Integrins: bidirectional, allosteric signaling machines.

Authors:  Richard O Hynes
Journal:  Cell       Date:  2002-09-20       Impact factor: 41.582

2.  IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

Authors:  Aihua Li; Seema Dubey; Michelle L Varney; Bhavana J Dave; Rakesh K Singh
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

Review 3.  Alternatively spliced tissue factor. A crippled protein in coagulation or a key player in non-haemostatic processes?

Authors:  Y W van den Berg; H H Versteeg
Journal:  Hamostaseologie       Date:  2010-08       Impact factor: 1.778

4.  Low density lipoprotein receptor-related protein mediates apolipoprotein E inhibition of smooth muscle cell migration.

Authors:  Debi K Swertfeger; Guojun Bu; David Y Hui
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

5.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.

Authors:  Louise E Reynolds; Lorenza Wyder; Julie C Lively; Daniela Taverna; Stephen D Robinson; Xiaozhu Huang; Dean Sheppard; Richard O Hynes; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

6.  Role of the phosphatidylinositol 3-kinase/protein kinase B pathway in regulating alternative splicing of tissue factor mRNA in human endothelial cells.

Authors:  Andreas Eisenreich; Ronny Malz; Wojciech Pepke; Yunus Ayral; Wolfgang Poller; Heinz-Peter Schultheiss; Ursula Rauch
Journal:  Circ J       Date:  2009-07-13       Impact factor: 2.993

7.  Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma.

Authors:  Dietmar Abraham; Karin Zins; Mouldy Sioud; Trevor Lucas; Romana Schäfer; E Richard Stanley; Seyedhossein Aharinejad
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

8.  Alternatively spliced tissue factor induces angiogenesis through integrin ligation.

Authors:  Y W van den Berg; L G van den Hengel; H R Myers; O Ayachi; E Jordanova; W Ruf; C A Spek; P H Reitsma; V Y Bogdanov; H H Versteeg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-29       Impact factor: 11.205

Review 9.  Will the real plaque vasculature please stand up? Why we need to distinguish the vasa plaquorum from the vasa vasorum.

Authors:  Zorina S Galis; Susan M Lessner
Journal:  Trends Cardiovasc Med       Date:  2009-04       Impact factor: 6.677

Review 10.  Vascular integrins: therapeutic and imaging targets of tumor angiogenesis.

Authors:  Curzio Rüegg; Gian Carlo Alghisi
Journal:  Recent Results Cancer Res       Date:  2010
View more
  10 in total

Review 1.  Role of the protein C receptor in cancer progression.

Authors:  Wolfram Ruf; Florence Schaffner
Journal:  Thromb Res       Date:  2014-05       Impact factor: 3.944

Review 2.  Tissue factor and cancer.

Authors:  Wolfram Ruf
Journal:  Thromb Res       Date:  2012-10       Impact factor: 3.944

3.  Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice.

Authors:  Jing Wang; Sagarika Chakrabarty; Quyen Bui; Wolfram Ruf; Fahumiya Samad
Journal:  Am J Pathol       Date:  2014-12-02       Impact factor: 4.307

Review 4.  "Soluble Tissue Factor" in the 21st Century: Definitions, Biochemistry, and Pathophysiological Role in Thrombus Formation.

Authors:  Vladimir Y Bogdanov; Henri H Versteeg
Journal:  Semin Thromb Hemost       Date:  2015-09-26       Impact factor: 4.180

5.  Tissue factor/factor VIIa signalling promotes cytokine-induced beta cell death and impairs glucose-stimulated insulin secretion from human pancreatic islets.

Authors:  Desirée Edén; Agneta Siegbahn; Dariush Mokhtari
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

6.  Antibody-based targeting of alternatively spliced tissue factor: a new approach to impede the primary growth and spread of pancreatic ductal adenocarcinoma.

Authors:  Dusten Unruh; Betül Ünlü; Clayton S Lewis; Xiaoyang Qi; Zhengtao Chu; Robert Sturm; Ryan Keil; Syed A Ahmad; Timofey Sovershaev; Mariette Adam; Patrick Van Dreden; Barry J Woodhams; Divya Ramchandani; Georg F Weber; Janusz W Rak; Alisa S Wolberg; Nigel Mackman; Henri H Versteeg; Vladimir Y Bogdanov
Journal:  Oncotarget       Date:  2016-05-03

Review 7.  Tissue factor structure and function.

Authors:  Saulius Butenas
Journal:  Scientifica (Cairo)       Date:  2012-12-26

8.  Alternatively spliced tissue factor is not sufficient for embryonic development.

Authors:  Susanna H M Sluka; Alexander Akhmedov; Johannes Vogel; Dusten Unruh; Vladimir Y Bogdanov; Giovanni G Camici; Thomas F Lüscher; Wolfram Ruf; Felix C Tanner
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

Review 9.  Tissue factor in tumor microenvironment: a systematic review.

Authors:  Xiao Han; Bo Guo; Yongsheng Li; Bo Zhu
Journal:  J Hematol Oncol       Date:  2014-08-01       Impact factor: 17.388

Review 10.  [Advances on mechanisms of coagulation with non-small cell lung cancer].

Authors:  Yanhua Li; Suju Wei
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2013-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.